{"title": "Ghrelin-induced growth hormone secretion in humans", "url": "https://eje.bioscientifica.com/view/journals/eje/143/6/R11.xml", "author": "R Peino and R Baldelli\u2026", "abstract": "Objective Recent trials suggest that using ergot-derived dopamine agonists such as cabergoline in the treatment of Parkinson's disease is associated with an increased risk of valvular heart disease. However, the dose of cabergoline used to treat hyperprolactinaemia \u2026", "eprint": "https://eje.bioscientifica.com/view/journals/eje/175/1/R11.xml"}